Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axovant Sciences Ltd (NQ: AXON )

1.220 USD UNCHANGED
Last Price Updated: 6:35 PM EST, Feb 13, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Axovant Sciences Ltd

< Previous 1 2 3 Next >
Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small... 
From GlobeNewswire News Releases
Hercules Capital Announces Multiple Outstanding Achievements by Numerous Investment Portfolio Companies
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture growth stage companies backed by some of the leading U.S.... 
From Business Wire News Releases
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies, today provided financial results and corporate updates for its third fiscal quarter and nine months ended... 
From GlobeNewswire News Releases
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies, today announced that the company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference.... 
From GlobeNewswire News Releases
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
- In addition to Roivant, four Vants will be presenting at JPM this year 
From PR Newswire
Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Canopy Growth... 
From GlobeNewswire News Releases
Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership
Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines.... 
From PR Newswire
Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross... 
From GlobeNewswire News Releases
Axovant Sciences Announces Public Offering of Common Shares
Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In... 
From GlobeNewswire News Releases
Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
Axovant Sciences (NASDAQ: AXON), a clinical-stage company focused on innovative gene therapies for neurological and neuromuscular diseases, today announced that it has licensed exclusive worldwide... 
From GlobeNewswire News Releases
Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, today reported topline results of the 34-patient, exploratory phase 2 clinical study of nelotanserin for the treatment of REM... 
From GlobeNewswire News Releases
Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
Axovant Sciences (NASDAQ: AXON), a clinical-stage company developing innovative gene therapies for neurological conditions, today announced feedback from a face-to-face pre-IND meeting with the U.S.... 
From GlobeNewswire News Releases
Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline
Axovant Sciences (NASDAQ: AXON), a company developing innovative gene therapies for neurological and neuromuscular diseases, today announced the addition of five senior team members to strengthen its... 
From GlobeNewswire News Releases
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
Axovant Sciences (NASDAQ: AXON) today provided financial results and corporate updates for its second fiscal quarter ended September 30, 2018. 
From GlobeNewswire News Releases
Oxford BioMedica notes that Axovant doses first patient in clinical study of AXO-Lenti-PD, a novel gene therapy for patients with Parkinson’s disease
From GlobeNewswire News Releases
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease
Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in a clinical study of AXO-Lenti-PD... 
From GlobeNewswire News Releases
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teva Pharmaceutical... 
From GlobeNewswire News Releases
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy
Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases, today announced upcoming presentations regarding its... 
From GlobeNewswire News Releases
Axovant to Present at Two Upcoming Investor Conferences
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at... 
From GlobeNewswire News Releases
Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases
- Respivant to be led by Bill Gerhart, former CEO of Patara Pharma and Elevation Pharmaceuticals 
From PR Newswire
Axovant to Present at Upcoming Investor Conferences
Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a corporate overview at... 
From GlobeNewswire News Releases
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
Axovant Sciences (NASDAQ:AXON) today announced corporate updates and financial results for its first fiscal quarter ended June 30, 2018. 
From GlobeNewswire News Releases
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of... 
From GlobeNewswire News Releases
Axovant to Present at First Annual Roivant Pipeline Day
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30... 
From GlobeNewswire News Releases
Thinking about buying stock in Axovant Sciences, Cronos Group, Micron, Netflix or AT&T?
InvestorsObserver issues critical PriceWatch Alerts for AXON, CRON, MU, NFLX, and T. 
From PR Newswire
Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease
Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into an exclusive worldwide licensing agreement with... 
From Business Wire News Releases
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Axovant Sciences (NASDAQ:AXON) today announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an... 
From GlobeNewswire News Releases
Axovant to Present at Two Upcoming Investor Conferences
Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018 at... 
From GlobeNewswire News Releases
Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion
Axovant Sciences (NASDAQ:AXON) today announced that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has... 
From GlobeNewswire News Releases
Technical Perspectives on Biotech Stocks -- Axovant Sciences, Aytu BioScience, BeiGene, and Bellicum Pharma
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AXON, AYTU, BGNE, and BLCM which can be accessed for free by signing up to... 
From PR Newswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.